LFCR

Lifecore is a fully integrated CDMO with a stable top line — FY2025 revenue of $129M was essentially flat (+0.5%), as 23% growth in HA manufacturing ($38.8M) offset a 7% decline in CDMO ($90.1M, hurt by a completed development project, a customer working down inventory, and a customer termination). Gross margin held at a modest 31.3% (down from 32.6%). On the surface this reads like a slow-turning turnaround, and management's MD&A leans hard on 'significant improvements to our revenue generating capacity, financial position... and stock exchange compliance.' But the operating line is still negative (-$17.2M operating income, -13.4% margin), so the business does not yet cover its own cost structure.

The balance sheet is where the thesis breaks. Stockholders' equity has collapsed 88% to just $1.34M against $192M of liabilities — a 143.6x liabilities/equity ratio that leaves essentially no cushion, with a -$205M accumulated deficit. Long-term debt is $130M and the current portion jumped 264% to $3.44M, yet cash is only $8.27M and operating cash flow was negative (-$206K) even before $13.4M of capex. The MD&A flags a related-party credit facility carrying embedded call/put derivatives that mark to fair value each period and can be triggered on default or change of control — a structure that both drains cash via interest (the gap between -$17.2M operating and -$38.7M net income is ~$21.5M of non-operating cost) and signals financing fragility. Share count also rose 21.1%, diluting holders as the company funds itself.